Tarke Alison, Zhang Yun, Methot Nils, Narowski Tara M, Phillips Elizabeth, Mallal Simon, Frazier April, Filaci Gilberto, Weiskopf Daniela, Dan Jennifer M, Premkumar Lakshmanane, Scheuermann Richard H, Sette Alessandro, Grifoni Alba
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
Department of Experimental Medicine and Center of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, 16132, Italy.
bioRxiv. 2023 Jan 5:2023.01.04.522794. doi: 10.1101/2023.01.04.522794.
The Coronavirus (CoV) family includes a variety of viruses able to infect humans. Endemic CoVs that can cause common cold belong to the alphaCoV and betaCoV genera, with the betaCoV genus also containing subgenera with zoonotic and pandemic concern, including sarbecoCoV (SARS-CoV and SARS-CoV-2) and merbecoCoV (MERS-CoV). It is therefore warranted to explore pan-CoV vaccine concepts, to provide adaptive immune protection against new potential CoV outbreaks, particularly in the context of betaCoV sub lineages. To explore the feasibility of eliciting CD4 T cell responses widely cross-recognizing different CoVs, we utilized samples collected pre-pandemic to systematically analyze T cell reactivity against representative alpha (NL63) and beta (OC43) common cold CoVs (CCC). Similar to previous findings on SARS-CoV-2, the S, N, M, and nsp3 antigens were immunodominant for both viruses while nsp2 and nsp12 were immunodominant for NL63 and OC43, respectively. We next performed a comprehensive T cell epitope screen, identifying 78 OC43 and 87 NL63-specific epitopes. For a selected subset of 18 epitopes, we experimentally assessed the T cell capability to cross-recognize sequences from representative viruses belonging to alphaCoV, sarbecoCoV, and beta-non-sarbecoCoV groups. We found general conservation within the alpha and beta groups, with cross-reactivity experimentally detected in 89% of the instances associated with sequence conservation of >67%. However, despite sequence conservation, limited cross-reactivity was observed in the case of sarbecoCoV (50% of instances), indicating that previous CoV exposure to viruses phylogenetically closer to this subgenera is a contributing factor in determining cross-reactivity. Overall, these results provided critical insights in the development of future pan-CoV vaccines.
冠状病毒(CoV)家族包括多种能够感染人类的病毒。可引起普通感冒的地方性冠状病毒属于α冠状病毒属和β冠状病毒属,β冠状病毒属还包含一些具有人畜共患病和大流行风险的亚属,包括严重急性呼吸综合征冠状病毒(SARS-CoV)和严重急性呼吸综合征冠状病毒2(SARS-CoV-2)所属的严重急性呼吸综合征冠状病毒亚属(sarbecoCoV)以及中东呼吸综合征冠状病毒所属的中东呼吸综合征冠状病毒亚属(merbecoCoV)。因此,有必要探索泛冠状病毒疫苗概念,以提供针对新的潜在冠状病毒爆发的适应性免疫保护,特别是在β冠状病毒亚谱系的背景下。为了探索引发广泛交叉识别不同冠状病毒的CD4 T细胞反应的可行性,我们利用大流行前收集的样本,系统分析了针对代表性α冠状病毒(NL63)和β冠状病毒(OC43)引起普通感冒的冠状病毒(CCC)的T细胞反应性。与先前关于SARS-CoV-2的研究结果相似,S、N、M和nsp3抗原对两种病毒均具有免疫优势,而nsp2和nsp12分别对NL63和OC43具有免疫优势。接下来,我们进行了全面的T细胞表位筛选,鉴定出78个OC43特异性表位和87个NL63特异性表位。对于选定的18个表位子集,我们通过实验评估了T细胞交叉识别属于α冠状病毒属、严重急性呼吸综合征冠状病毒亚属和β-非严重急性呼吸综合征冠状病毒亚属组的代表性病毒序列的能力。我们发现α和β组内存在普遍的保守性,在89%与序列保守性>67%相关的实例中通过实验检测到交叉反应性。然而,尽管存在序列保守性,但在严重急性呼吸综合征冠状病毒亚属的情况下观察到的交叉反应性有限(50%的实例),这表明先前接触与该亚属在系统发育上更接近的病毒是决定交叉反应性的一个因素。总体而言,这些结果为未来泛冠状病毒疫苗的开发提供了关键见解。